

Technical Data Sheet

InVivoMAb anti-human CTLA-4 (CD152)



Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: BE0190
Clone: BN13
Isotype: Mouse IgG2a, κ
Recommended Isotype Control(s): InVivoMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Immunogen: Human CTLA-4 recombinant protein
Reported Applications: *in vitro* CTLA-4 neutralization
Flow cytometry
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: ≤ 1 EU/mg (≤ 0.001 EU/ μ g)
Determined by LAL gel clotting assay
Purity: $\geq 95\%$
Determined by SDS-PAGE
Sterility: 0.2 μ m filtered
Production: Purified from cell culture supernatant in an animal-free facility
Purification: Protein G
RRID: [AB_10950635](https://ebi.github.io/RRID/AB_10950635)
Molecular Weight: 150 kDa

Description

The BN13 monoclonal antibody reacts with human CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. CTLA-4 is a 33 kDa cell surface receptor encoded by the *Ctla4* gene that belongs to the CD28 family of the Ig superfamily. CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses. CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity. The critical role of CTLA-4 in immune down-regulation has been demonstrated in CTLA-4 deficient mice, which succumb at 3-5 weeks of age due to the development of a lymphoproliferative disease. CTLA-4 is among a group of inhibitory receptors being explored as cancer treatment targets through immune checkpoint blockade. The BN13 antibody has been shown to neutralize CTLA-4 *in vitro*.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.


Application References

For a complete list of references, visit https://bioxcell.com/be0190?bxcs=9k1b3a#tab_references or scan the QR code below.



Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail technicalservice@bioxcell.com.



Bio X Cell, LLC
<https://bioxcell.com>
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC